The scientific focus adapted
to express the optimum potential
of your molecule

Marketing:
Unparalleled vision in metabolic disorders and risk assessment expertise for post-marketing studies and drug repositioning.

HeartArteryMacrophageLiverMusclePancreasAdipose Tissue

Preclinical development:
In-house predictive models and tracer technologies enable the generation of Proof of Concept efficacy data for your drugs.

Discovery:
Screening and lead validation utilize a dedicated research platform which combine with our focused scientific vision.

Home > News > The International Liver Congress – Annual EASL meeting (April 10-14, 2019), in Vienna, Austria.

News detail

Return to all news & events

04/03/2019 The International Liver Congress – Annual EASL meeting (April 10-14, 2019), in Vienna, Austria.

Physiogenex will attend The International Liver Congress on April 12, 2019 during the Poster Session NAFLD: Experimental and pathophysiology  (9am – 5pm).

Dr. François Briand, our Director of Research and Business Development, will present a poster dealing with our NASH models.

Poster (#4725)  The benchmarks obeticholic acid and elafibranor show variable effects on NASH and hepatic fibrosis in diet-induced or chemically-induced animal models”.

Dr. Briand will be happy to discuss with you about your preclinical NASH project , explore it and share with you his expertise. Please Contact us to set-up an appointment.

About us

Physiogenex is a leading preclinical research organization providing non clinical services in metabolic disorders and complications.

We offer in vivo translational diseases models as well as ex vivo assays to support efficacy and pharmacological assays. We have a strong expertise on metabolic diseases, diabetes, insulin resistance, obesity, dyslipidemia, liver diseases (NASH to fibrosis) and renal complications.